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Introduction: In this report, we describe an unusual case of post-operative Acremonium falciforme endophthalmitis
with orbital and extra-orbital involvement following combined cataract and glaucoma surgery.
Case presentation: A 68-year-old Caucasian man with glaucoma presented with endophthalmitis characterized by
pain, redness and impaired vision in the left eye fifteen days after combined cataract and filtering surgery. He
subsequently underwent a pars plana vitrectomy, with vitreous sampling, silicone oil placement and intra-vitreal
injection of antibiotics, but only after a second vitrectomy we identified Acremonium falciforme as the causative
agent for the endophthalmitis. An antifungal systemic and topical therapy was started, but meanwhile the infection
extended to orbital and peri-orbital tissues. Following these procedures, even if the eye went slowly in phthisis, we
were able to limit the further extension and circumscribe the orbital and extra-orbital involvement.
Conclusion: To our knowledge, this report is the first describe Acremonium falciforme endophthalmitis with orbital and
extra-orbital involvement, following anterior segment combined surgery. Ophthalmologists and physicians should be
aware of the extension risk of a fungal panophthalmitis, but also to potentially serious side effects related to systemic
therapy.
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Post-operative fungal endophthalmitis is a rare complica-
tion that frequently carries a worse prognosis than bacter-
ial endophthalmitis. Approximately 90% of post-operative
endophthalmitis cases develop after cataract surgery [1-5],
and bacteria, such as coagulase-negative staphylococci
and Propionibacterium acnes, are the most common
causes. Various fungi are known to be major causes of
delayed-onset endophthalmitis [6], and the prognosis
appears to be related to many factors, including the ex-
tent of intra-ocular involvement, the timing and mode
of intervention and the virulence of the organism involved.
Although the outcome may be positive with vision* Correspondence: carlo.cagini@unipg.it
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unless otherwise stated.recovery in some patients, in other cases the prognosis
is not favorable [6]. Orbital and extra-orbital involve-
ment is a rare complication of fungal endophthalmitis.
We describe a case of a patient with Acremonium
falciforme endophthalmitis which developed two weeks
after combined cataract and glaucoma surgery with im-
portant involvement of orbital and extra-orbital struc-
tures. To the best of our knowledge, there have been no
other similar cases described in the literature to date.Case presentation
A 68-year-old Caucasian man with glaucoma who was
receiving chronic therapy was referred to our institution
with a diagnosis of post-operative endophthalmitis in the
left eye. The patient had inflammation in the left eye
that had started a few days earlier and was associated
with impaired vision. Two weeks before presentation heLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Left eye of the patient before vitrectomy. Pre-operative
photograph shows diffuse subconjunctival hemorrhage and
complete filling of the anterior chamber with hypopyon.
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coma shunt implant at another eye clinic.
Upon presentation, he had a corrected distance visual
acuity (CDVA) of 20/80 in the right eye, a cortical and
nuclear cataract and filtering bleb that had developed
after previous glaucoma surgery. Upon presentation, he
had a corrected distance visual acuity (CDVA) of 20/80
in the right eye, a filtering bleb and a cortical and nu-
clear cataract developed after the previous glaucoma sur-
gery performed two years earlier.
A glaucomatous optic disc excavation was present and
the visual field was significantly narrowed in the inferior
nasal area. He was receiving therapy with bimatoprost
eyedrops in this eye.
His CDVA in the left eye was 1/200, and he showed
marked conjunctival injection, corneal edema, inflamma-
tory aqueous cells (Tyndall 3+) and fibrin on the front
face of the intra-ocular lens (IOL). The glaucoma shunt
implant (EX-PRESS® Glaucoma Filtration Device; Alcon
Laboratories, Fort Worth, TX, USA) was in site with a
non-inflamed filtering bleb. There was dense vitritis, and
it was impossible to visualize the retina and the optic
disc. A 25-gauge pars plana vitrectomy (PPV) was per-
formed using a CONSTELLATION® vitrectomy system
(Alcon Surgical, Tokyo, Japan), and infusion fluid (BSS
PLUS®; Alcon Surgical) was devoid of any antibiotics. At
a site 4.0mm from and parallel to the limbus, three tro-
cars were inserted at a 30° angle (one in the inferonasal
area for the infusion), creating tunnel sclerotomies. Ini-
tially, a vitreous sample (with the infusion channel closed)
was collected using the vitrectome, then the remaining vi-
trectomy with hyaloid removal was completed. The vitre-
ous cavity was filled with silicone oil, and ceftazidime and
vancomycin were injected intravitreally. All the scleroto-
mies were sutured because of the risk of leakage.
During surgery, the retina appeared to be covered by
an abundant fibrinous exudation. After surgery, the pa-
tient’s CDVA was 1/30, and therapy with topical vanco-
mycin (50mg/ml) and ceftazidime (50mg/ml) eyedrops
six times per day was started. The IOL and the glaucoma
valve were left in place because the patient strongly
expressed this desire, given the low visual acuity of the
other eye. Cultures taken from the aqueous and vitreous
were negative, and his early post-operative course was un-
eventful and without signs of significant inflammation, ex-
cept for a thin layer of fibrin on the front face of the IOL.
He was discharged some five days after surgery, and he
continued the therapy at home and returned for scheduled
checks. During these checks, his CDVA was 1/20 and
there were no signs of inflammation in the anterior cham-
ber; however, the retina could not be easily evaluated,
owing to fibrin plaque on the surface of the IOL.
Forty-five days after this surgery, he experienced acute,
increasing pain in the left eye with severe inflammation,corneal edema, anterior chamber inflammation (Tyndall
4+) and hypopyon occupying three-fourths of the anter-
ior chamber (Figure 1). He underwent a new anterior
chamber washout with aqueous sample and a vitrectomy
with silicone oil tamponade.
Two days after his second surgery, an increase of
intra-ocular pressure was observed (treated with topical
and systemic therapy) associated with the formation of a
thick white plaque on the anterior surface of the IOL
that prevented observation of the retina and the optic
disc. His CDVA at this time was 1/200. Systemic therapy
with fluconazole (400mg/day) and amphotericin B
0.15% eyedrops (six times per day) was started, which
led to progressive reduction of the exudation in the anter-
ior chamber. One week later, Acremonium falciforme
species were identified in cultures obtained from samples,
and the systemic therapy was switched to intravenous
voriconazole 6mg/kg every 12 hours for the first day,
then 4mg/kg intravenously every 12 hours for 10 days,
followed by 200mg orally every 12 hours. This therapy
led to a further reduction of the exudation in the an-
terior chamber. After seven days, it was possible to
evaluate the red reflex of the retina, which revealed a
slight improvement of CDVA to 1/60.
Ten days later, the patient presented with liver func-
tion test impairment and sharp pain in the left orbital
region that radiated to the same side of the head due to
extension of the inflammatory process to the orbit and
peri-orbital tissue. A magnetic resonance imaging (MRI)
scan showed that there was evidence of left orbital inflam-
mation with inhomogeneous appearance of the eyeball
and peri-bulbar inflammation, which was more evident at
the lacrimal gland (Figure 2). A faint hyperintensity of the
optic nerve in T2 and slight signs of inflammation at the
apex of the left orbital cavity were reported (Figure 3). At
Figure 2 Coronal T1-weighted magnetic resonance imaging
scan. Contrast agent was injected with fat suppression mode on.
Peri-bulbar inflammation is more evident at the left lacrimal gland
(red arrow).
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nisone (25mg twice daily for two weeks) was started,
which led to significant pain reduction. The condition of
the left eye showed a gradual further improvement, but it
was necessary to stop the systemic antifungal therapy after
22 days because of liver toxicity. The topical drugs were
continued unchanged. One month later, unremitting pain in
the orbital region reappeared; therefore, systemic antifungalFigure 3 Coronal short tau inversion recovery magnetic
resonance imaging scan. Faint hyperintensity of the left optic
nerve can be seen in T2 (red arrow).therapy (voriconazole 6mg/kg intravenously every 12
hours for the first day, then 4mg/kg intravenously
every 12 hours for 10 days, followed by 200mg orally every
12 hours) combined with pain therapy (acetaminophen
500mg/, codeine 30mg/day and gabapentin 300mg/day)
was restarted, which led to progressive reduction of the
patient’s ocular and peri-orbital pain.
Immediately after this therapy, the patient showed
significant ingravescent neurologic symptoms with vis-
ual hallucinations, postural instability, slight ideomotor
slowdown, retropulsion and dynamic ataxia. Brain MRI
excluded vascular lesions, but this examination highlighted
enhancement of the left temporal muscle associated with
ectasia of contiguous vessels, it was an evident index of in-
flammation (Figure 4). His electroencephalography results
were normal, and lumbar puncture was performed to ex-
clude infectious processes of the brain. Cerebrospinal fluid
was clear, but showed albumin cytological dissociation.
Once infectious or inflammatory processes were excluded,
the cause of neurological symptoms was attributed to a
toxic effect induced by the recently introduced analgesic
therapy. After one week, we observed an improvement in
neurologic symptomatology, but it was indispensable to
maintain therapy with paracetamol, codeine and gabapen-
tin. During this period, while the patient’s left eye began to
show signs of phthisis, CDVA in his right eye decreased to
20/100 due to worsening of the cataract that was associ-
ated with progressive impairment of the optic nerve.Figure 4 Coronal contrast-enhanced, T1-weighted magnetic
resonance imaging scan. Contrast agent was injected with fat
suppression mode on,, and enhancement of the left temporal
muscle (red arrow) associated with ectasia of contiguous vessels
(green arrow) is evident as an index of inflammation.
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cause of an increase in the cholestasis and hepatic cytoly-
sis indices, but topical therapy was maintained for nine
months. During this period, the patient was observed with
close follow-up. He had no more signs of ocular inflam-
mation; however, the white plaque on the anterior surface
of the IOL did not disappear (Figure 5), and his pain was
controlled with decreasing doses of analgesic oral therapy.
The left eye’s condition deteriorated slowly into phthisis.
Conclusions
In this report, we describe an unusual manifestation of
post-operative Acremonium falciforme endophthalmitis
with serious orbital and extra-orbital involvement in a
fully immunocompetent patient. To our knowledge,
Acremonium falciforme endophthalmitis after cataract
surgery has been described only once previously [7]
and no cases of Acremonium panophthalmitis have
previously been reported in the literature.
Fungal intra-ocular infections sometimes show a specific
pattern that can guide the specialist toward a prompt diag-
nosis. In other cases, they present an absolutely nonspecific
manifestation and can be identified only by using one or
more microbiological tests with aqueous or vitreous sam-
ples. This could be due to an uncertain medical history or,
as in our case, to the advanced stage of inflammation at
the time of the first visit. There are several reported cases
of post-surgical, delayed-onset endophthalmitis. The wide
majority of these cases are caused by bacteria. Only 0% to
4% of post-surgical endophthalmitis cases are caused by
fungal infection. Therefore, after the negative outcome of
the first cultures and in consideration of the severity of the
clinical appearance in our patient, we established that a
first therapeutic approach with broad-spectrum antibiotics
associated with pars plana vitrectomy (PPV), is widelyFigure 5 Final appearance of the eyeball. Photograph shows a
wide corneal leukoma with limbal neovascularization involving the
superotemporal area and pupillary region.deemed the gold standard in fungal endophthalmitis
management.
Acremonium species, formerly termed Cephalosporium
species, are soil fungi that are ubiquitous environmental
contaminants. They are saprophytic molds and have sept-
ate, colorless hyphae like those of other hyaline molds
[8-10]. Although invasive disease may occur in an im-
munocompromised person, most cases of human disease,
unlike other filamentous fungi, occur in immunocompe-
tent hosts [11]. Ocular involvement of Acremonium
falciforme is very uncommon.
Exogenous fungal endophthalmitis is known to occur in
a variety of clinical settings, including contiguous spread
of fungal keratitis, penetrating keratoplasty, cataract sur-
gery, glaucoma filtering surgery, retinal detachment
surgery and many others [9]. Moreover, Acremonium
species may post-operatively invade through wounds,
contaminated air solutions (such as humidifier fluid)
or objects [10].
The initial symptoms of Acremonium endophthalmitis
are similar to those of most delayed-onset endophthal-
mitis, including mild pain, redness, floaters and slightly
decreased visual acuity [7-10]. The interval between sur-
gery and endophthalmitis onset ranges from two to six
weeks [12].
At present, no treatment modality for these fungal in-
fections has been well established. Weissgold et al. [9]
suggested that higher or repeated drug doses of ampho-
tericin B (possibly in combination with vitrectomy) may
be necessary to adequately treat these kinds of infec-
tions. Cameron et al. [7] reported that Acremonium re-
mains viable in the anterior chamber despite surgical
removal of the bulk of the fungal mass and treatment
with several antifungal medications, including topical
natamycin, topical amphotericin B, subconjunctival mi-
conazole injection and oral ketoconazole. Joe et al. [13]
treated the remaining white plaque in the anterior
chamber after vitrectomy with voriconazole medication
for six months. Mattei et al. [14] reported that voricona-
zole treatment appeared to be very effective in their case
report of fungemia caused by Acremonium. Voriconazole
is a triazole derivative that achieves a therapeutic level in
aqueous and vitreous liquids by oral administration [14,15].
The possibility that the fungus remains in the glau-
coma shunt implant or on the IOL despite topical and
systemic therapy is well-known, and all the implants
must be removed to eradicate the infection. We did not
perform such a surgical procedure in our patient, first
because he refused and later because of his poor general
condition. We were aware of the risk of using systemic
steroids to treat fungal infections, but the infectologist
arranged this therapy while the patient was already tak-
ing a systemic antifungal drug. Moreover, we were
faced with a post-operative infection with a subsequent
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ited to the eye and the intra-orbital structures. We
were unable to deliver the systemic antifungal therapy
as we wished because of the risk of liver toxicity. Des-
pite this rare infection that spread to the orbital, peri-
orbital and temporal tissues, as well as the adverse
events induced by the drugs (that is, liver toxicity and
neurological impairment caused by antifungal therapy
and analgesic drugs, respectively), we were able to manage
the inflammatory damage and its complications.
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